tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Axsome Therapeutics price target raised to $198 from $189 at RBC Capital
PremiumThe FlyAxsome Therapeutics price target raised to $198 from $189 at RBC Capital
5d ago
Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
Premium
The Fly
Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
5d ago
Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley
Premium
The Fly
Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley
5d ago
Axsome Therapeutics files automatic mixed securities shelf
PremiumThe FlyAxsome Therapeutics files automatic mixed securities shelf
6d ago
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
Premium
Ratings
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
6d ago
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Justify Buy Rating
Premium
Ratings
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Justify Buy Rating
6d ago
Axsome Therapeutics’ Promising Phase 3 Trial for Shift Work Disorder
PremiumCompany AnnouncementsAxsome Therapeutics’ Promising Phase 3 Trial for Shift Work Disorder
13d ago
Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention
Premium
Company Announcements
Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention
13d ago
Axsome Therapeutics Advances Phase 3 Trial for Binge Eating Disorder Treatment
Premium
Company Announcements
Axsome Therapeutics Advances Phase 3 Trial for Binge Eating Disorder Treatment
13d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100